This study assesses Senegal’s performance against the 7-1-7 approach, a benchmark for outbreak preparedness, focusing on infectious disease detection, notification, and response from 2022 to 2023. Using secondary national surveillance data, the analysis included socio-demographic, clinical, and laboratory information, with data visualized using ArcGIS.

Findings showed a median detection period of 12 days, twice the recommended duration, due to factors like healthcare-seeking behavior and lab processing times. Notification was relatively efficient, with a median of 1 day post-lab confirmation. However, delays in activating the national Emergency Operations Center (EOC) were noted.

Despite limitations such as incomplete arbovirus data and an unstructured response data system, the study highlights the need to align current surveillance indicators with the 7-1-7 metrics, digitalize the notification system, and empower additional laboratories. These interventions are essential for improving public health responses, enhancing health outcomes, and increasing community resilience in Senegal.

The authors have declared no competing interest.

The author(s) received no specific funding for this work

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Senegalese Ministry of Health, Department of Prevention, granted permission to use deidentified case base surveillance data collected during the study period in the country. No local ethical committee approval was required for this secondary data analysis of routine surveillance data.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data and related metadata underlying the findings reported in this manuscript will be available upon request